Core Insights - Capricor Therapeutics announced new data from the Phase 3 HOPE-3 clinical trial of Deramiocel for Duchenne muscular dystrophy (DMD), highlighting its potential impact on patients' daily lives and long-term outcomes [1][3][5] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate currently in late-stage development for DMD [10] - The company has received multiple designations for Deramiocel, including Orphan Drug Designation from the U.S. FDA and EMA, and Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. [9] Clinical Trial Results - The HOPE-3 trial results showed a significant reduction in myocardial fibrosis measured by late gadolinium enhancement (LGE) on cardiac MRI (p=0.022) [6] - In patients with baseline cardiomyopathy, Deramiocel demonstrated a 3.3 percentage-point improvement in left ventricular ejection fraction (LVEF) versus placebo (p=0.017) [6] - The Global Statistical Test (GST) composite endpoint indicated a statistically significant overall treatment benefit favoring Deramiocel (p=0.017) [6] - The Duchenne Video Assessment (DVA) showed approximately 83% slowing of disease progression compared to placebo (p=0.018) [6] Regulatory Status - The Biologics License Application (BLA) for Deramiocel is currently under FDA review, with a target action date of August 22, 2026 [3][5] Collaboration and Commercialization - Capricor has entered into an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization and distribution of Deramiocel for DMD in the United States and Japan, pending regulatory approval [12]

Core Insights - Capricor Therapeutics announced that the results from its Phase 3 HOPE-3 clinical study of Deramiocel for Duchenne muscular dystrophy (DMD) will be presented at the 2026 Muscular Dystrophy Association (MDA) Clinical and Scientific Conference [1][2] Company Overview - Capricor Therapeutics is a biotechnology company focused on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead product candidate for DMD [10] - The company has received Orphan Drug Designation from both the U.S. FDA and the European Medicines Agency (EMA) for Deramiocel, along with Regenerative Medicine Advanced Therapy (RMAT) designation in the U.S. and Advanced Therapy Medicinal Product (ATMP) designation in Europe [7][8] Clinical Study Details - The HOPE-3 trial is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of Deramiocel in DMD patients, involving 106 subjects [9] - The trial includes both non-ambulatory and ambulatory boys, who receive either Deramiocel or placebo every three months for a total of four doses during the first year [9] Regulatory Efforts - Capricor has submitted the clinical study report (CSR) for HOPE-3 to the FDA as part of the ongoing Biologics License Application (BLA) review process, aiming for a potential approval decision [2][3] - The CSR submission addresses items outlined in the Complete Response Letter (CRL) from the FDA and supports the ongoing review of the BLA for Deramiocel [3] Presentation Details - The late-breaking presentation at the MDA Conference is scheduled for March 11, 2026, at 2:45 p.m. ET, focusing on the musculoskeletal and cardiac benefits of Deramiocel in DMD [3]

Core Insights - Capricor Therapeutics, Inc. announced positive topline results from its Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) [1][2] - A community webinar hosted by Parent Project Muscular Dystrophy (PPMD) will discuss these results and their implications for regulatory discussions with the FDA [2] Company Overview - Capricor Therapeutics is focused on developing cell and exosome-based therapeutics, with Deramiocel as its lead product candidate for DMD [4] - The company has demonstrated Deramiocel's immunomodulatory and anti-fibrotic effects, which help preserve cardiac and skeletal muscle function in DMD patients [4] - Capricor is also advancing its proprietary StealthX™ platform for targeted delivery of therapeutics in preclinical development [4] Regulatory and Commercialization Efforts - Capricor has entered an exclusive agreement with Nippon Shinyaku Co., Ltd. for the commercialization and distribution of Deramiocel in the U.S. and Japan, pending regulatory approval [6]

Core Insights - Capricor Therapeutics announced positive topline results from the Phase 3 HOPE-3 trial for Deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) [1][2] - The trial demonstrated statistically significant improvements in both skeletal and cardiac function, reinforcing previous findings from the HOPE-2 trial [2][5] - The results are expected to support regulatory approval following a Complete Response Letter from the FDA earlier this year [2][5] Study Details - HOPE-3 was a randomized, double-blind, placebo-controlled trial involving 106 participants across 20 U.S. clinical sites, with an average age of approximately 15 years [2][11] - Participants received intravenous Deramiocel at 150 million cells per infusion or placebo every three months for 12 months [2][12] - The study maintained a favorable safety and tolerability profile consistent with prior clinical experience [2][5] Efficacy Results - The primary endpoint, Performance of Upper Limb (PUL v2.0), showed a 54% slowing of progression compared to placebo (p=0.029) [3][5] - The key secondary endpoint, Left Ventricular Ejection Fraction (LVEF), demonstrated a 91% improvement (p=0.041) [3][5] - Statistically significant results were achieved across all controlled secondary endpoints [5] Clinical Implications - The findings indicate meaningful treatment effects on both upper limb function and cardiomyopathy, addressing critical aspects of DMD [5][6] - The preservation of cardiac function is particularly significant, as cardiomyopathy is the leading cause of mortality in DMD [6][8] - The results provide renewed confidence for families seeking therapies that maintain functional ability and protect heart health [6][10] Company Background - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for rare diseases, with Deramiocel as its lead candidate for DMD [13] - Deramiocel has received Orphan Drug Designation from the FDA and EMA, along with other designations that may facilitate regulatory approval [10][15] - The company is committed to advancing innovative therapies and has a proprietary platform for targeted delivery of therapeutics [13]

Core Insights - Capricor Therapeutics is focused on developing therapies for Duchenne cardiomyopathy and has faced regulatory challenges but is working on a clear path forward for approval [2][4] - The company has made significant progress with its exosome platform, StealthX™, which has received FDA clearance for clinical trials [4][6] - Financial results indicate a net loss for the second quarter of 2025, with revenues dropping to zero compared to the previous year [8][10] Corporate Update - Capricor aims to resubmit its Biologics License Application (BLA) for Deramiocel based on existing data, with additional data from the HOPE-3 trial expected in Q4 2025 [4][5] - The FDA has accepted all observations from the Pre-License Inspection, marking a milestone in regulatory progress [4][5] - The company is preparing for a Type A meeting with the FDA to discuss the approval pathway [4][5] Financial Performance - Cash position as of June 30, 2025, was approximately $122.8 million, down from $151.5 million at the end of 2024 [7][26] - Revenues for Q2 2025 were $0, a decrease from approximately $4.0 million in Q2 2024, and for the first half of 2025, revenues were also $0 compared to approximately $8.9 million in the first half of 2024 [8][10] - Total operating expenses for Q2 2025 were approximately $27.7 million, up from $15.6 million in Q2 2024 [9][10] Clinical Development - The HOPE-3 Phase 3 clinical trial is ongoing, with topline data expected in Q4 2025 [5][6] - The FDA has cleared the IND for the StealthX™ exosome-based vaccine, marking its first clinical entry [4][6] - Orphan Drug Designation has been granted for Deramiocel in Becker muscular dystrophy, expanding its therapeutic strategy [5][6]

Core Insights - Capricor Therapeutics announced positive four-year safety and efficacy results for Deramiocel, its lead cell therapy candidate for Duchenne Muscular Dystrophy (DMD) [1][3] - The findings will be presented at the PPMD 2025 Annual Conference, highlighting the importance of addressing both cardiac and skeletal muscle functions in DMD treatment [1][4] Efficacy Results - After four years of treatment, Deramiocel-treated patients showed a median change of -0.5 points compared to baseline, indicating clinical benefit, especially in patients with baseline LVEF >45% [2] - The treatment also slowed skeletal muscle disease progression, with a smaller average decline in Performance of the Upper Limb (PUL v2.0) in the fourth year (0.6 points) compared to the first year (1.8 points) [3][7] Safety Profile - Deramiocel maintained a favorable safety profile throughout the study, reinforcing its potential as a therapeutic option for DMD [3][7] Regulatory Progress - Capricor is in the process of obtaining regulatory approval for Deramiocel, with its Biologics License Application (BLA) under priority review and no evidence of delays in discussions with the FDA [4][10] Study Background - The HOPE-2 study was a randomized, double-blind, placebo-controlled Phase 2 trial, with patients receiving intravenous infusions of Deramiocel (150 million cells) every three months [5] - Following the study, all patients entered a treatment gap phase before enrolling in the HOPE-2 Open-Label Extension (OLE) study, which continues to monitor safety and efficacy [5] About Duchenne Muscular Dystrophy - DMD is a severe genetic disorder affecting approximately 15,000 individuals in the U.S., characterized by progressive muscle degeneration and leading to cardiomyopathy, which is a major cause of mortality [6][9] About Deramiocel - Deramiocel (CAP-1002) consists of allogeneic cardiosphere-derived cells (CDCs) known for their immunomodulatory and anti-fibrotic properties, which may help preserve cardiac and skeletal muscle function in DMD [8][10] - The therapy has received multiple designations from regulatory agencies, including Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation [9]

Core Insights - Capricor Therapeutics is progressing towards the FDA's PDUFA target action date of August 31, 2025, for its Biologics License Application (BLA) for deramiocel, a cell therapy for Duchenne muscular dystrophy (DMD) cardiomyopathy [1][2] - The FDA's mid-cycle review meeting indicated no significant deficiencies in the BLA submission, and an advisory committee meeting will be scheduled [1][2] - DMD is a severe genetic disorder affecting approximately 15,000-20,000 patients in the U.S., characterized by progressive muscle weakness and heart failure [3] Company Overview - Capricor Therapeutics focuses on developing cell and exosome-based therapeutics for rare diseases, with deramiocel as its lead product candidate [7] - Deramiocel consists of allogeneic cardiosphere-derived cells (CDCs) that have shown immunomodulatory and anti-fibrotic effects in clinical studies [4][7] - The company has received Orphan Drug Designation from the FDA and EMA for deramiocel, along with RMAT and ATMP designations to support its regulatory pathway [5] Clinical Development - The BLA submission for deramiocel is backed by data from Phase 2 trials (HOPE-2 and HOPE-2 OLE) and comparisons to FDA-funded datasets on DMD-cardiomyopathy [2] - Efficacy data from the ongoing HOPE-3 study is not included in the current BLA submission [2] - Capricor has entered an agreement with Nippon Shinyaku Co., Ltd. for the exclusive commercialization of deramiocel in the U.S. and Japan, pending regulatory approval [9]